Directory

Sudhir Borgonha

Translational Science Director | MD

Sudhir is a physician researcher with over 15 years of experience leading early stage projects and companies. Before coming to FARF, he was the Medical Director at Strand Genomics, where he was instrumental in developing customized gene panels in rare diseases and cancer, including launching a liquid biopsy test. He oversaw clinical reporting in collaboration with clinicians across the globe for over 5,000 patients per year, of which over a 1,000 were in rare diseases. As Translational Science Director, Sudhir leads development of FA translational science by working with academic and industry partners to pursue clinical research opportunities to better understand and treat FA. He manages translational projects including the development of a clinical registry and tissue bank.

A graduate of St. John’s Medical College, Bangalore and the Sloan School of Management, MIT, Sudhir is passionate about integrating emerging technologies into medicine. He is an aspiring writer and still has mixed feelings about why Bob Dylan won the Nobel prize in literature and Philip Roth didn’t.

The Latest

News & Events

2025 Research Updates

Research is the answer to one day making FA a treatable, manageable disease. Here, you'll discover the most recent strides in FA research and activities funded by FCF. Every quarter, we'll bring you updates on newly funded grants, ongoing projects, and significant milestones.

Read More >

In Loving Memory of Imroze Marzban Ardeshir

April 15, 1983 – December 27, 2017By Daisy & Marzban Ardeshir The story below was shared by Imroze’s parents, Daisy and Marzban Ardeshir, in remembrance of their daughter’s strength, grace, and enduring spirit. Our second child, Imroze, was diagnosed with...

Read More >

A Remarkable Gift for the FA Community

We’re thrilled to share that Rena and Paul Rice, parents of two children with Fanconi anemia—Sydney (19) and Blake (25)—have made an extraordinary commitment to the FA community: a gift of $100,000 per year for the next three years to...

Read More >